Deutsche Bank AG Buys 12,940 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Deutsche Bank AG boosted its holdings in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 8.8% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 159,752 shares of the company's stock after acquiring an additional 12,940 shares during the quarter. Deutsche Bank AG owned 0.27% of Twist Bioscience worth $7,424,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Twist Bioscience by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock worth $269,860,000 after purchasing an additional 189,791 shares in the last quarter. ARK Investment Management LLC boosted its holdings in shares of Twist Bioscience by 4.4% in the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company's stock worth $260,040,000 after purchasing an additional 237,772 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in Twist Bioscience by 54.6% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock valued at $69,972,000 after acquiring an additional 532,040 shares during the period. Geode Capital Management LLC boosted its holdings in Twist Bioscience by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company's stock valued at $63,895,000 after acquiring an additional 6,908 shares during the period. Finally, First Light Asset Management LLC purchased a new stake in Twist Bioscience during the 4th quarter valued at about $56,984,000.

Twist Bioscience Stock Up 1.7%

Shares of Twist Bioscience stock traded up $0.52 on Tuesday, reaching $30.91. The company's stock had a trading volume of 983,018 shares, compared to its average volume of 972,899. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of -9.14 and a beta of 2.54. The firm's fifty day simple moving average is $37.47 and its two-hundred day simple moving average is $43.15. Twist Bioscience Co. has a 52 week low of $28.46 and a 52 week high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The firm had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Equities analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on TWST shares. Guggenheim restated a "buy" rating and set a $50.00 target price on shares of Twist Bioscience in a report on Tuesday, May 6th. Robert W. Baird dropped their target price on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Barclays dropped their target price on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. The Goldman Sachs Group dropped their price objective on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Finally, Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $50.40.

Insider Activity at Twist Bioscience

In related news, COO Patrick John Finn sold 2,058 shares of the business's stock in a transaction dated Wednesday, April 23rd. The stock was sold at an average price of $39.99, for a total value of $82,299.42. Following the sale, the chief operating officer now directly owns 265,460 shares in the company, valued at approximately $10,615,745.40. The trade was a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Emily M. Leproust sold 1,726 shares of the business's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $41.68, for a total value of $71,939.68. Following the completion of the sale, the chief executive officer now owns 660,966 shares in the company, valued at $27,549,062.88. This represents a 0.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,991 shares of company stock worth $742,654. Corporate insiders own 3.01% of the company's stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.